Systemic JIA: Where Are We


Published on

Karen Onel, M.D.

Division of Pediatric Rheumatology
University of Chicago

Published in: Health & Medicine
  • Be the first to comment

Systemic JIA: Where Are We

  1. 1. Systemic Juvenile IdiopathicArthritis:Where are We?Karen Onel, M.D.Division of Pediatric RheumatologyUniversity of Chicago
  2. 2. A child goes to see thedoctor with a history offever. They have knee painand swelling too!What’s wrong?How can we figure this out?Is this Systemic JIA?
  3. 3. Juvenile Idiopathic Arthritis Most common rheumatic disease of childhood Important cause of disability and blindness Syndrome of diverse etiologies--Idiopathic Criteria – Age less than 16 – Arthritis (vs. arthralgia)-Joint inflammation not just pain – Duration > 6 weeks
  4. 4. Idiopathic We still don’t understand why children get systemic JIA Not likely genetic-rare to have 2 family members involved Some people think it belongs with the autoinflammatory and periodic fever syndromes
  5. 5. Types of JIA Oligoarthritis Extended Oligoarthritis Polyarthritis (either RF+ or -) Psoriatic Arthritis Enthesitis-related Arthritis Systemic Onset
  6. 6. Epidemiology Incidence--10/100,000/year in US Prevalence--100/100,000 children in US Age at onset extremely rare prior to 6 months Peak ages-- – 1-3 years (girls) – 9 years (boys and girls) Lower extremities most often involved
  7. 7. Much more about SystemicJuvenile Idiopathic ArthritisStill’s DiseaseRarest subtype-at most 10%
  8. 8. Lots of things give kids feversand joint pains and jointswelling Infections – Infections in the bone or joint Cancer – Especially cancer that involves the bone marrow  Leukemia, lymphoma, neuroblastoma Other rheumatologic illness – Lupus, Dermatomyositis, Vasculitis – Reactive Arthritis – Polyarticular JIA can present with fevers
  9. 9. Systemic Onset JIA-Systemic Arthritis Joints may or may not be involved at the beginning Sex ratio: equal May occur at any age (even adults) Uveitis rare Systemic signs (fever, rash, abnormal labs) may precede the development of arthritis by years (even 10!)
  10. 10. Clinical Features Diagnostic hallmark--high spiking fevers with daily return to normal
  11. 11. Clinical Features Classic rash—usually flat red spots that come and go but can be hives Rash is transient--Koebner’s phenomenon Rash can be very itchy
  12. 12. Clinical Features Joints can be severely involved Often very severe hip involvement Joint and muscle pain may be worse when children have fever
  13. 13. Clinical Features Heart and lungs can be involved Liver and spleen can be involved as well Enlarged lymph nodes are common
  14. 14. Laboratory Evaluation Lab tests show a great deal of systemic stress- ESR, platelet and white blood cells can be very elevated. It would be surprising if they were normal at the beginning Anemia of chronic disease is common and children may not respond to oral iron supplementation.
  15. 15. What about MacrophageActivation Syndrome Acute Hemophagocytic Syndrome – normal, activated macrophages (scavenger white blood cells) eat up red and white blood cells, as well as platelets. – Liver function tests, ferritin and markers of coagulation (blood clotting) are often abnormal – Often early in disease or with flares – Viruses probably play a role, especially EBV which causes mono – Treated with steroids, cyclosporine as well as other medications
  16. 16. How do we make thediagnosis? Above all, JIA is a clinical diagnosis Does the patient have swollen joints not just joint pain? How long has the swollen joint been there? Are they below 16? Do they have any other medical problems? What is the fever pattern Do they have signs of MAS? Did you look for other possibilities?
  17. 17. What about labs? ANA is not useful to make the diagnosis of Systemic JIA but helps to rule out other diseases RF useful for identifying RF+ poly but should be negative here Expect acute phase reactants to be abnormal in active Systemic Arthritis Exclude other causes of joint pain and swellingBUT Systemic JIA is a clinical disease—there is not one lab test that definitively makes the diagnosis
  18. 18. Consensus Treatment PlansDefinition of Systemic JIAPatient should be/have1. Age 6 months to 18 years2. Fever for at least 2 weeks†3. Arthritis in ≥1 joints (6 weeks duration not required)‡4. At least 1 of the following: a. Evanescent erythematous rash b. Generalized lymphadenopathy c. Hepatomegaly or splenomegaly d. Pericarditis, pleuritis, and/or peritonitis
  19. 19. Consensus Treatment Plans- ExclusionsPatient should not have 1. Infection, including concomitant active or recurrentchronic bacterial, fungal, or viral infection at presentation,nor underlying infection that may mimic initial presentationof systemic JIA2. Malignancy From De Witt, et al, A C and R, 64: 1001-1010, 2012
  20. 20. Treatment
  21. 21. NSAID’s Even in the biologic age, NSAIDs are important. Gastritis is common but ulcers are rare Liquid preparations--ibuprofen, naproxen, meloxicam and indomethacin Others can be dissolved in water or crushed which destroys the enteric coating
  22. 22. Methotrexate We still don’t really know how it works Use of folic acid does not interfere with function like it does for cancer Very slow onset of activity—often 2-3 months Sq form has better absorption but hard to find currently due to drug shortage. Nausea is common but can and should be treated Risk of liver toxicity. Need to follow Liver function tests every 2 months at least
  23. 23. Corticosteroids Continue to play an important role in the treatment of JIA Growth side-effects especially problematic in pediatrics Alternate day steroids generally not effective at controlling inflammation Can be given by mouth, intravenous or in the joint —depends on what you need
  24. 24. Cyclosporine From the transplanters but at lower doses Prevents T cells from becoming activated, decreasing inflammation Mostly useful in the setting of MAS where it plays a critical role
  25. 25. Other DMARDs Thalidomide Hydroxychloroquine Azathioprine Leflunamide Sulfasalazine
  26. 26. The cytokine soup… We love our biologics!!!!
  27. 27. RECOGNITION OF OUTCOMESBy the early 1990s, long-term studies showed: Long-term morbidity: • ↑ disability • ↓ quality of life Mortality We needed a new strategy!!
  28. 28. BIOLOGICS These drugs are targeted therapies directedagainst specific pathologic mechanisms which are present in inflamed joints.
  29. 29. APC
  30. 30. Pro-inflammatory
  31. 31. TNF Blockade TNF, made by macrophages and T cells is clearly important in the pathogenesis of synovitis and joint destruction Five available agents to interfere with TNF signaling (two are approved for kids with JIA) Response in 70% polyarticular disease within 4 weeks with sustained response—Getting people off is more complicated BUT-doesn’t work for Systemic JIA
  32. 32. Well…What does work?
  33. 33. Role of IL-1 IL-1 is responsible for bone and cartilage destruction in arthritis IL-1 causes white blood cells to flock to site of infection and to reset the center of the brain responsible for regulating body temperature leading to fever. IL-1 is, therefore, called an endogenous pyrogen IL-1 is also responsible for increased pain associated with fever.
  34. 34. Anikinra (Kineret TM ) Anakinra is a recombinant version of the human Interleukin-1 receptor antagonist (IL- 1Ra) and blocks IL-1 by competitively inhibiting IL-1 binding to the Interleukin-1 type I receptor (IL-1RI) Given once daily as a sq injection Most common side effect is injection site pain
  35. 35. ANAKINRA: CLINICAL USESUsed in RA, but especially useful in: Systemic-Onset Arthritis Gout Cryopyrin-associated periodic syndromes (CAPS): • Muckle-Wells syndrome • Chronic infantile, neurologic, cutaneous and articular syndrome (CINCA) / neonatal-onset multisystem inflammatory disease (NOMID) • Familial cold autoinflammatory syndrome
  36. 36. Anakinra and systemic JIAFrom Nigrovic, et al. A and R 63:545-555, 2011
  37. 37. New Il-1 blockers Rilonocept (ArcalystTM) Canakinumab (IlarisTM) These drugs are currently indicated for the treatment of CAPS but testing in Systemic JIA is ongoing
  38. 38. Role of IL-6 Endothelial cells Mesenchymal cells, Monocytes/ fibroblasts/ macrophages synoviocytes T-cell activation IL-6 Hepatocytes Acute-phase response Maturation of Hepcidin, CRP megakaryocytes ↓ CYP450 B-cells Osteoclast activation Bone resorption Thrombocytosis Auto-antibodies (RF) Hyper-γ-globulinemiaAdapted from 1 Firestein GS. Nature. 2003; 423:356-361.2 Smolen JS, et al. Nat Rev Drug Disc. 2003; 2:473-488. Disc.
  39. 39. Tocilizumab (Actemra TM ) Tocilizumab is a humanized, monoclonal antibody that targets the IL-6 receptor and inhibits IL-6 signaling It is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. It is given intravenously every two weeks Common side effect upper respiratory tract infection, headache, nasopharyngitis and diarrhea. Can cause abnormal liver function tests, decreased white blood cells, allergic reactions, and lipid problems
  40. 40. Actemra and Systemic JIAJIA absence of fever at Week 12 (TENDER TRIAL)
  41. 41. Rituximab (Rituxan TM ) Currently indicated for relapsed or refractory lymphoma and RA Used for many different types of rheumatic diseases Binds to CD20 antigen on normal and malignant pre-B and mature B cells One study showed potential for its use in Systemic JIA
  42. 42. We always want more Greedy, greedy, greedy
  43. 43. 2011 version
  44. 44. Maybe we just need to knowwhich path to follow… CARRA CONSENSUS TREATMENT PLANS
  45. 45. Stem Cell Transplant When all else fails, autologous stem cell transplantation has been used successfully. Should be done by a center with experience
  46. 46. Prognosis Better each year!!! 70-90% children with JIA have good outcome without serious disability The hardest part is getting children to be medicine free- that time will come! Delay in medical or physical therapy and undertreatment are associated with poor prognosis